MAGI3 and nonpapillary renal cell carcinoma: In a clinical study using IHC staining on ccRCC patients undergoing Sunitinib treatment, those with higher MAGI3 levels and lower phosphorylated ERK levels displayed a favorable response, while poor responders exhibited the opposite (Fig. 8A–C).